RIVFLOZA (Nedosiran Sodium) Patent Expiration, LOE Window & CMS Spending

RIVFLOZA (Nedosiran Sodium) by Novo Nordisk: FDA Orange Book core substance LOE 2038-10-12, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $62,880 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovo Nordisk
FDA Application & PathwayN215842 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-10-12
Last Listed Patent or Exclusivity Date2038-10-12
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($62,880 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.